Failure to Replicate Genetic Associations with Antidepressant Treatment Response in Duloxetine-Treated Patients

Biological Psychiatry

Volumn 67, Issue 11, 2010, Pages 1110-1113

  Perlis, Roy H ^a   Fijal, Bonnie ^b   Dharia, Sweta ^c   Heinloth, Alexandra N ^c   Houston, John P ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Lilly USA   (United States)

^c Statprobe   (United States)

Author keywords

ABCB1; GRIK4; OPRM1; phosphodiesterases; SLC6A4; SNP

Indexed keywords

DULOXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; THIOPHENES; TREATMENT OUTCOME;

EID: 77951880638     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2009.12.010     Document Type: Article

References (19)

1. Franchini L., Serretti A., Gasperini M., and Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 32 (1998) 255-259
2. Bozina N., Peles A.M., Sagud M., Bilusic H., and Jakovljevic M. Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. World J Biol Psychiatry 9 (2008) 190-197
3. Garriock H.A., Kraft J.B., Peters E.J., Jenkins G.D., Reinalda M.S., McGrath P.J., et al. Receptor is associated with response to antidepressant treatment (2008) Presented at the 7th Annual Pharmacogenetics in Psychiatry Meeting, April 4-5, 2008, New York, NY
4. Kraft J.B., Slager S.L., McGrath P.J., and Hamilton S.P. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 58 (2005) 374-381
5. Lesch K.P., and Gutknecht L. Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 1062-1073
6. Mrazek D.A., Rush A.J., Biernacka J.M., O'Kane D.J., Cunningham J.M., Wieben E.D., et al. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet 150B (2009) 341-351
7. Nikisch G., Eap C.B., and Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: A pilot study. Pharmacol Rev 58 (2008) 344-347
8. Paddock S., Laje G., Charney D., Rush A.J., Wilson A.F., Sorant A.J., et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR* D cohort. Am J Psychiatry 164 (2007) 1181-1188
9. Uhr M., Tontsch A., Namendorf C., Ripke S., Lucae S., Ising M., et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57 (2008) 203-209
10. Wong M.L., Whelan F., Deloukas P., Whittaker P., Delgado M., Cantor R.M., et al. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci U S A 103 (2006) 15124-15129
11. Kraft P. Curses-winner's and otherwise-in genetic epidemiology. Epidemiology 19 (2008) 649-651
12. Whitmyer V.G., Dunner D.L., Kornstein S.G., Meyers A.L., Mallinckrodt C.H., Wohlreich M.M., et al. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. J Clin Psychiatry 68 (2007) 1921-1930
13. Serretti A., Kato M., and Kennedy J.L. Pharmacogenetic studies in depression: A proposal for methodologic guidelines. Pharmacogenomics J 8 (2008) 90-100
14. Perlis R., Fijal B., Adams D., Sutton V., Trivedi M., and Houston J. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry 65 (2009) 785-791
15. Jurinke C., van den Boom D., Cantor C.R., and Koster H. Automated genotyping using the DNA MassArray technology. Methods Mol Biol 187 (2002) 179-192
16. Owens M.J., Morgan W.N., Plott S.J., and Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283 (1997) 1305-1322
17. Arias B., Catalan R., Gasto C., Gutierrez B., and Fananas L. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 23 (2003) 563-567
18. Durham L.K., Webb S.M., Milos P.M., Clary C.M., and Seymour A.B. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology 174 (2004) 525-529
19. Perlis R.H., Mischoulon D., Smoller J.W., Wan Y.J., Lamon-Fava S., Lin K.M., et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 54 (2003) 879-883